They found that APN treatment prevented the development of systolic dysfunction after myocardial infarction by inhibiting myocardial hypertrophy and interstitial fibrosis, and protecting cardiomyocyte and capillary loss [119]. This evidence concerns the gene ANPEP and cardiac hypertrophy.